People who are undergoing dialysis and have anemia caused by chronic kidney disease may receive a monthly injection of Omontys. This prescription drug is given through an intravenous (IV) infusion or as an injection just under the skin. It is given once a month and is approved for use in adults only. Side effects may include diarrhea, nausea, and shortness of breath.

In February 2013, Omontys was pulled from the market (all of the product was recalled) to investigate reports of dangerous allergic reactions, including fatal anaphylactic reactions, which appear to be occurring more frequently than anticipated. This medication will not be available until further notice.

What Is Omontys?

Omontys® (peginesatide) is a prescription medication approved to treat anemia caused by chronic kidney disease (CKD) in adults on dialysis. It is injected just once a month.
(Click Omontys Uses for more information on this topic, including possible off-label uses.)

Who Makes This Medication?

Omontys is jointly marketed by Affymax, Inc., and Takeda Pharmaceuticals America, Inc.

How Does Omontys Work?

Omontys belongs to a group of medications known as erythropoiesis-stimulating agents (ESAs). It works by stimulating the production of red blood cells by the bone marrow.

Clinical Effects

Studies have compared Omontys to epoetin alfa (a similar medication) or epoetin beta (a similar medication available in Europe) for treating anemia caused by chronic kidney disease. These studies evaluated the effectiveness of the medications by measuring the level of hemoglobin (a protein found in red blood cells). These studies showed that using Omontys once a month produced similar results as using epoetin one to three times a week.

Omontys Medication Information

Referring Pages:
Terms of Use
Advertise with Us
Contact Us
About eMedTV
Privacy Policy
Copyright © 2006-2020 Clinaero, Inc.
eMedTV serves only as an informational resource. This site does not dispense medical advice or advice of any kind. Site users seeking medical advice about their specific situation should consult with their own physician. Click Terms of Use for more information.